Aditxt Inc.

4.61
-0.97 (-17.38%)
At close: Apr 04, 2025, 3:59 PM
4.72
2.45%
After-hours: Apr 04, 2025, 05:55 PM EDT

Company Description

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming.

It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues.

The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies.

Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University.

The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021.

Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Aditxt Inc.
Aditxt Inc. logo
Country United States
IPO Date Jun 30, 2020
Industry Biotechnology
Sector Healthcare
Employees 47
CEO Amro A. Albanna

Contact Details

Address:
737 North Fifth Street
Richmond, Virginia
United States
Website https://www.aditxt.com

Stock Details

Ticker Symbol ADTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001726711
CUSIP Number 007025109
ISIN Number US0070256047
Employer ID 82-3204328
SIC Code 2834

Key Executives

Name Position
Amro A. Albanna Co-Founder, Chairman & Chief Executive Officer
Rowena Albanna Chief Operating Officer
Thomas J. Farley CPA Chief Financial Officer
Corinne D. Pankovcin CPA, M.B.A. Chief Mergers & Acquisitions Officer
Dr. Dolly B. Tyan D(ABHI), Ph.D. Senior Vice President of Clinical Development – Transplantation
Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D. Co-Founder, Chief Innovation Officer, Secretary & Director
Ge Chen M.D., M.S. Senior Vice President of Preclinical Research & Discovery
Jennifer Lee Director of Human Resources

Latest SEC Filings

Date Type Title
Apr 03, 2025 424B5 Filing
Apr 03, 2025 424B5 Filing
Mar 31, 2025 10-K Annual Report
Mar 31, 2025 8-K Current Report
Mar 28, 2025 8-K Current Report
Mar 25, 2025 8-K/A [Amend] Current Report
Mar 25, 2025 8-K/A [Amend] Current Report
Mar 24, 2025 8-K Current Report
Mar 24, 2025 8-K Current Report
Mar 17, 2025 8-K Current Report